 
Diode  Laser  for Non‐invasive  Fat Reduction  of the Abdomen  IRBVerCsioonnd1i.t0ions 
Protocol  #CS1317  19 September  2018  
Satisfied  at the Protocol  
Level  
Oct 11, 2018  
Clinical  Evaluation  of the Safety  and Efficacy  of a 
1060  nm Diode  Laser  for Non‐invasive  Fat Reduction  
of the Abdomen  
Protocol Identifying Number: CS1317  
Funded  by: Venus Concept  Ltd. 
Version Number: v 1.0  
19 September  2018  
[STUDY_ID_REMOVED]  
 
 
 
 
 
 
 
Sponsor  Contact  
 
Paul  Cardarelli  
Senior  Director,  Product  Marketing  and Clinical  Affairs  
Address:  Venus Concept Ltd.  
255 Consumers  Rd., Suite  110 
Toronto, Ontario  M2J 1R4  
Canada  
Telephone  888‐907‐0115  
E‐mail:  pcardarelli@venusconcept.com  
 
 
 
 
  24/09/18   
 
Signature  of Sponsor  Representative  Date:  (DD/MM/YYYY  
20182493  
ii  Table  of Contents  
LIST  OF ABBREVIATIONS ................................ ................................ ................................ ...........................  1 
STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ .................  2 
PROTOCOL  SUMMARY  ................................ ................................ ................................ ...............................  3 
SCHEMATIC  OF STUDY  DESIGN  ................................ ................................ ................................ ...............  4 
1 KEY ROLES  ................................ ................................ ................................ ................................ ...... 5 
2 INTRODUCTION:  BACKGROUND  INFORMATION  AND  SCIENTIFIC  RATIONALE  ......................  5 
2.1 Background  Information  ................................ ................................ ................................ ...........  5 
2.2 Rationale  ................................ ................................ ................................ ................................ .. 5 
2.3 Potential  Risks and  Benefits  ................................ ................................ ................................ .... 6 
2.3.1  Known Potential Risks  ................................ ................................ ...........................  6 
2.3.2  Known Potential Benefits  ................................ ................................ .......................  6 
3 OBJECTIVES  AND  PURPOSE  ................................ ................................ ................................ .........  7 
4 STUDY  DESIGN  AND  ENDPOINTS  ................................ ................................ ................................ . 7 
4.1 Description  of the Study  Design  ................................ ................................ ...............................  7 
4.2.1  Primary  EndpointS  ................................ ................................ ................................ . 7 
4.2.2  Secondary  Endpoints  ................................ ................................ .............................  7 
5 STUDY  ENROLLMENT  AND  WITHDRAWAL  ................................ ................................ ...................  8 
5.1 Participant  Inclusion  Criteria  ................................ ................................ ................................ .... 8 
5.2 Participant  Exclusion  Criteria  ................................ ................................ ................................ ... 8 
5.3 Strategies  for Recruitment  and Retention  ................................ ................................ ................  9 
5.4 Participant  Withdrawal or  termination  ................................ ................................ ......................  9 
5.4.1  Reasons  for Withdrawal  or Termination  ................................ ................................ . 9 
5.4.2  Handling  of Participant  Withdrawals or  termination  ................................ ...............  9 
5.5 Premature  Termination or  Suspension  of Study  ................................ ................................ ...... 9 
6 STUDY  device  ................................ ................................ ................................ ................................ . 11 
6.1 Study  device  and Control  Description  ................................ ................................ ....................  11 
6.1.1  Acquisition  ................................ ................................ ................................ ............  11 
6.1.2  Device  Specific Considerations  ................................ ................................ ...........  11 
6.2 Study  device  Accountability  Procedures  ................................ ................................ ................  11 
7 STUDY  PROCEDURES  AND  SCHEDULE  ................................ ................................ .....................  11 
7.1 Study  Procedures/Evaluations  ................................ ................................ ...............................  11 
7.1.1  Study  specific procedures  ................................ ................................ ....................  11 
7.2 Laboratory  Procedures/Evaluations  ................................ ................................ .......................  12 
7.2.1  Clinical  Laboratory  Evaluations  ................................ ................................ ............  12 
7.3 Study  Schedule  ................................ ................................ ................................ ......................  12 
7.3.1  Screening  ................................ ................................ ................................ .............  12 
7.3.2  Enrollment/Baseline  ................................ ................................ .............................  13 
7.3.3  Follow -up ................................ ................................ ................................ ..............  14 
7.3.4  Final  Study  Visit ................................ ................................ ................................ ... 14 
7.3.5  Early  Termination Visit  ................................ ................................ .........................  15 
7.3.6  UNSCHEDULED  Visit ................................ ................................ ..........................  15 
7.3.6  Schedule  of Events Table  ................................ ................................ ....................  15 
7.4 Justifi cation for  Sensitive  Procedures  ................................ ................................ ....................  15 
7.5 Concomitant  Medications, Treatments,  and Procedures  ................................ .......................  16 
7.6 Prohibited Medications,  Treatments,  and Procedures  ................................ ...........................  16 
iii  7.7 Prophylactic  Medications,  Treatments,  and Procedures  ................................ .......................  16 
7.8 Rescue  Medications,  Treatments,  and Procedures  ................................ ...............................  16 
8 ASSESSMENT  OF SAFETY  ................................ ................................ ................................ ...........  17 
8.1 Specification  of Safety  Parameters  ................................ ................................ ........................  17 
8.1.1  Definition of  Adverse Events (AE)  ................................ ................................ ....... 17 
8.1.2  Definition of Serious  Adverse  Events (SAE)  ................................ ........................  17 
8.1.3  Definition of  Unanticipated  Problems (UP)  ................................ ..........................  17 
8.2 Classification  of an Adverse  Event  ................................ ................................ ........................  18 
8.2.1  Severity  of Event  ................................ ................................ ................................ .. 18 
8.2.2  Relationship  to Study  Agent  ................................ ................................ .................  18 
8.2.3  Expectedness ................................ ................................ ................................ ....... 18 
8.3 Time  Period  and Frequency  for Event  Assessment  and Follow -Up ................................ ...... 18 
8.4 Reporting Procedures  ................................ ................................ ................................ ............  19 
8.4.1  Adverse  Event  Reporting  ................................ ................................ .....................  19 
8.4.2  Serious  Adverse  Event  Reporting  ................................ ................................ ........  19 
8.4.3  Unanticipated  Problem  Reporting  ................................ ................................ ........  20 
8.4.4  Reporting of  Pregnancy  ................................ ................................ .......................  20 
8.5 Study  Halting  Rules ................................ ................................ ................................ ................  20 
8.6 Safety  Oversight ................................ ................................ ................................ .....................  20 
9 CLINICAL  MONITORING  ................................ ................................ ................................ ................  21 
10 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................  21 
10.1 Statistic al and Analytical  Plans  ................................ ................................ ..............................  21 
10.2 Statistical  Hypotheses  ................................ ................................ ................................ .....................  21 
10.3 Analysis  Datasets  ................................ ................................ ................................ ..................  22 
10.4 Description  of Statistical Methods  ................................ ................................ ..........................  22 
10.4.1  General Approach  ................................ ................................ ................................  22 
10.4.2  Analysis  of the primary  endpoints  ................................ ................................ ........  23 
10.4.3  Analysis  of the secondary  endpoints  ................................ ................................ ... 23 
10.4.5  Safety  analysis  ................................ ................................ ................................ ..... 24 
10.4.6  Adherence and  Retention  Analyses ................................ ................................ ..... 25 
10.4.7  Baseline  Descriptive  Statistics  ................................ ................................ .............  25 
10.4.8  Planned  Interim  Analyses  ................................ ................................ ....................  25 
10.4.10  Multiple Comparison/Multiplicity  ................................ ................................ ...........  25 
10.4.11  Tabulatio n of Individual  Response  Data  ................................ ..............................  25 
10.4.12  Exploratory  Analyses  ................................ ................................ ...........................  25 
10.5 Sample  Size ................................ ................................ ................................ ...........................  25 
10.6 Measures  to Minimize  Bias ................................ ................................ ................................ .... 26 
10.6.1  Enrollment/  Randomization/  Masking  Procedures  ................................ ...............  26 
10.6.2  Evaluation  of Success  of Blinding  ................................ ................................ ........  26 
10.6.3  Breaking  the Study  Blind/Participant  Code  ................................ ..........................  27 
11 SOURCE  DOCUMENTS AND  ACCESS  TO SOURCE DATA/DOCUMENTS  ...............................  27 
12 QUALITY  ASSURANCE  AND  QUALITY  CONTROL  ................................ ................................ ...... 27 
13 ETHICS/PROTECTION  OF HUMAN  SUBJECTS  ................................ ................................ ...........  28 
13.1 Ethical  Standard  ................................ ................................ ................................ .....................  28 
13.2 Institutional  Review  Board  ................................ ................................ ................................ ..... 28 
13.3 Informed  Cons ent Process  ................................ ................................ ................................ .... 28 
iv  13.3.1  Consent/assent  and Other  Informational  Documents  Provided  to Participants  ... 28 
13.3.2  Consent Procedures and  Documentation  ................................ ............................  28 
13.4 Participant  and data Confidentiality  ................................ ................................ .......................  29 
13.4.1  Research  Use of Stored Human  SAMPLES, SPECIMENS  or Data  ....................  29 
14 DATA  HANDLING  AND  RECORD  KEEPING  ................................ ................................ .................  29 
14.1 Data  Collection  and Management  Responsibilities  ................................ ...............................  29 
14.2 Study  Records Retention  ................................ ................................ ................................ ....... 30 
14.3 Protocol  Deviations  ................................ ................................ ................................ ................  30 
14.4 Publication  and Data Sharing  Policy  ................................ ................................ ......................  30 
15 STUDY  ADMINISTRATION  ................................ ................................ ................................ .............  31 
15.1 Study  Leadership  ................................ ................................ ................................ ...................  31 
16 CONFLICT  OF INTEREST  POLICY  ................................ ................................ ................................  31 
17 LITERATU RE REFERENCES  ................................ ................................ ................................ .........  31 
APPENDIX  ................................ ................................ ................................ ................................ ..................  32 
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018   
 LIST  OF ABBREVIATIONS  
 
 
AE Adverse Event  
Analysis of Covariance  
Body  Mass  Index  
Code of Federal Regulations  
Case Report Form  
Continuous  Wave  
Food and Drug Administration  
Good Clinical Practice  
Graphical  User  Interface  
International  Conference  on Harmonisation  
International Conference on Harmonisation Guidance for Industry, Good Clinical  
Practice:  Consolidated Guidance  
International Committee of Medical Journal Editors  
Institutional  Review  Board  
International  Organization  for Standardization  Good  Clinical Practices  for Clinical  
Medical Dictionary for Regulatory Activities  
Principal  Investigator  
Quality Control  
Serious  Adverse  Event  
Statistical Analysis Plan  
Subcutaneous  
Simple Lifestyle Indicator Questionnaire  
Ultrasound  
Unanticipated  Problem  ANCOVA  
BMI 
CFR 
CRF 
CW 
FDA 
GCP 
GUI 
ICH 
ICH E6 
ICMJE  
IRB 
ISO 14155:2011  
MedDRA  
PI 
QC 
SAE 
SAP 
SC 
SLIQ  
US 
UP 
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  2 of 32  
 STATEMENT  OF COMPLIANCE  
 
The trial  will be  carried  out in accordance  with Good  Clinical  Practice  (GCP) as  required  by the  following : 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part  
46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) or equivalent local  
regulatory  regulations  or guidelines  
• ICH E6 
• ISO 14155:2011  
 
All key personnel (all individuals responsible for the design and conduct of this trial) have  
completed  Human  Subjects  Protection  Training.  
 
 
I agree to ensure that all staff memb ers involved in the conduct of this study are informed about their  
obligations  in meeting  the above  commitments.  
 
 
Principal  Investigator:     
Print/Type  Name  
 
 
Signed:  Signature  Date:     
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  3 of 32  
  
 
 
TITLE  Clinical  Evaluation  of the Safety  and Efficacy  of a 1060nm  Diode  Laser for  Non - 
Invasive Fat  Reduction  of the Abdomen  
SUMMARY  Open -label, baseline -controlled, evaluator -blind multi -center study evaluating a  
1060 nm diode laser for non -invasive fat reduction of the abdomen. The study  
will enroll up to 50 subjects requesting non -invasive lipolysis of the abdomen.  
Each subje ct will receive a single study treatment.  Subjects will be followed at  
six weeks  and twelve  weeks post -treatment.  Twelve  week  outcomes  will be 
compared  to baseline.  
OBJECTIVE  The objective  of this clinical  study  is to assess  the safety and  efficacy  of using  a 
1060  nm diode laser  for non-invasive  fat reduction  of the abdomen.  
ENDPOINT  Primary  endpoints  
• Photographic evaluation by independent, blinded reviewers with  
correct identification of pre -treatment baseline images when compared  
to post -treatment  images  taken at  twelve  weeks  
Secondary  endpoints  
• To determine the change in thickness of the adipose layer as measured  
by ultrasound (US) at twelve weeks post -treatment as compared to  
baseline  
• To determine the change in abdominal circumferen ce at twelve weeks  
post -treatment  as compared  to baseline  
• To assess subject satisfaction with treatment at twelve weeks using the  
5-Point  Likert Subject  Satisfaction  Scale  
Safety  
• Subject’s assessment of discomfort and pain post -treatment as  
measured by  the Wong -Baker Faces  Pain  rating  scale  
• Subjects  experiencing  a treatment -related  adverse  event  (AE) 
POPULATION  The study  will enroll  up to 50 male  and female  subjects,  18 to 60 years  of age 
who  are seeking  fat reduction  of the abdomen.  
PHASE  Pre-Market  
NUMBER  OF SITES  Up to 5 sites  
DESCRIPTION  OF 
DEVICE  The investigational device (Venus Bliss ™) is a non -invasive medical aesthetic  
device  designed  for body  contouring.  The device is  comprised  of a console,  four  
1060 nm diode laser applicators (60 mm x 60 mm).  A belt is included to allow  
the operator to  secure  the laser applicators  on the lipolysis  treatment  area,  
allowing  hands  free operation.  
STUDY  DURATION  Twelve  months  
PARTICIPANT  
DURATION  Three  months  
PROTOCOL  SUMMARY  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  4 of 32  
  
 
 
 
 
Screening  Obtain  informed  consent  
Physical  exam,  demographics,  medical  history,  concomitant  medication  
Screen  potential  subjects  by inclusion  and exclusion  enrollment  criteria  
  
 
Visit 1  
Day 0 Weight,  urine  pregnancy  test 
AEs, concomitant medication, lifestyle questionnaire, abdominal circumference  
Baseline photographs  for blinded evaluation  
Baseline ultrasound for subcutaneous fat assessment  
Administer  study  treatment  
Visual  pain  scale,  immediate  response  
  
 
Visit 2  
Week  6 Weight  
AEs,  concomitant  medication,  abdominal  circumference  
Photographs  for blinded  evaluation  
Ultrasound  for subcutaneous  fat assessment  
 
 
 
Visit 3  
Month  3 Final Assessments  
Weight  
AEs,  concomitant  medication  
Lifestyle questionnaire, subject satisfaction, subject treatment evaluation  
Abdominal  circumference  
Photographs  for blinded  evaluation  
Ultrasound  for subcutaneous  fat assessment  
SCHEMATIC  OF STUDY  DESIGN  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  5 of 32  
  
 
 
Paul  Cardarelli  
Senior Director, Product Marketing and Clinical Affairs  
Address: Venus  Concept  Ltd. 
255 Consumers Rd., Suite 110  
Toronto, Ontario  M2J 1R4  
Canada  
Telephone  888-907-0115  
E-mail:  pcardarelli@venusconcept.com  
 
 
 
There are multiple, non -invasive fat reduction procedures currently available for non -surgical body - 
contouring.  Technologies include cryolipolysis, radiofrequency, high frequency focused ultrasound, and  
photobiomodulation.  All modalities deliver some form of energy that creates changes in the adipocytes.  
Studies  show  that these  therapies are  safe and effective.  
 
Many non -invasive laser technologies have been studied with the efficacy of laser therapy purported to  
be related to the wavelength and the energy delivered.  Initial lasers studied include the neodymium - 
doped yttrium aluminum garnet (Nd:YAG) lase r delivering 1064nm and 1320nm wavelengths.  Diode  
lasers were introduced delivering energy at 980nm, 924nm, 975nm and 920nm wavelengths.  The quest  
for the most effective laser diode wavelength for lipolysis with the least adverse effect continues, most  
recently with the  1060nm  wavelength.  
 
The 1060nm laser diode leads to the injury of the adipocytes through direct heating of the tissue.  The 
energy delivered creates movement within the molecules of the exposed tissue, which then generates  
heat.  A controlled temperature of 42 -47 °C must be maintained at the site of adipocytes.  At this  
temperature, the cell membranes of the adipocytes lose their structural integrity leading to cell death.  
Upon cell injury and death, the body naturally eliminates the contents of the adipocytes with results at 6  
weeks but optimally at 12 weeks.  The 1060nm wavelength has a particular affinity for adipocytes with  
low absorption within the dermis.  In addition, melanin is minimally targeted so the device can be used  
in all skin types.  (Schilling  L et al)  
 
This study will investigate whether a single treatment with a 1060nm laser delivered by the Venus Bliss ™ 
investigational device is safe and efficacious for the reduction of abdominal fat.  In addition, the study  
will investi gate  whether  the effects  of this single  treatment  are maintained  at six  months  post -therapy.  
 
 
The use of 1060nm laser diode technology has been shown in clinical studies to be safe and effective for  
lipolysis.  The objective of this clinical study is to evaluate the safety and efficacy of the use of the Venus  
Bliss ™ investigational  medical  device for  non-invasive  fat reduction  of the abdomen.  
1 KEY ROLES  
2 INTRODUCTION:  BACKGROUND  INFORMATION  AND  SCIENTIFIC  RATIONALE  
2.1 BACKGROUND  INFORMATION  
2.2 RATIONALE  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  6 of 32  
  
The use of the Venus Bliss ™ has been determined to present non -significant ris k in accordance with 21  
CFR 812.3  for the intended  use in this study,  because  the device  is not: 
 
• Intended  as an implant;  
• purported  or represented  to be  for use supporting  or sustaining  human life;  
• for use of substantial importance in diagnosing, curing, mitigating, or treating disease, or  
otherwise preventing  impairment  of human  health;  or 
• Otherwise  presenting  a potential  for serious  risk to  the health,  safety,  or welfare  of a subject.  
Furthermore, the use of the non -invasive 1060nm la ser diode technology for lipolysis has been reported  
without incidents or significant complications by Bass LS et al, 2018; Decorato, JW et al, 2017 and Katz B  
et al,  2018.  
 
This study will be conducted in compliance with the protocol and according to Good Clinical Practice  
(GCP)  standards.  
 
 
 
Expected adverse events of the laser treatment procedure include transient tenderness, erythema,  
edema, and/or induration in the treated area lasting from one to three weeks after the treatment.  In 
addition, other adverse events may include and include localized firmness, ecchymosis, skin burn,  
hyperpigmentation, hypopigmentation, blister and changes in skin laxity.  Rarely, skin con tour  
irregularities, dimpling, asymmetry (uneven appearance due to uneven anatomy or uneven treatment of  
the area), necrosis (tissue death), hardness and nodules occur.  Protective laser eyewear will be worn by  
the subject and  operator providing  the procedu re. 
 
The device has a contact tissue cooling system in place during the procedure to minimize thermal  
discomfort and prevent damage to the treatment area.  Expected adverse events related to the contact  
cooling  include  tingling,  itching, decreased  sensation,  numbness,  erythema  and tenderness.  
 
The boundaries of the treatment area will be marked with a semi -permanent tattoo ink using a  
microblade.  The ink markings should dissipate within one year.  Microblade marking may be associated  
with tenderness.  
 
There are minimal risks associated with the use of ultrasound.  The use of the ultrasound may cause  
redness  of the  skin.  Skin rashes rarely  occur  with the  use of ultrasound  gel. 
 
Risks will be mitigated by conducting this protocol with an investigator experienced in the therapeutic  
area of the clinical investigation.  The investigator will be trained by the sponsor on the use of the  
device.  The device design incorporates safety mechanisms which minimize risks.  Patients will also be  
rigorously  screened  prior  to their  enrollment and  rigorously  followed  over  the course of  the study.  
 
 
If the subject agrees to participate in this study, he/she will be contributing to the understanding of the  
safety  and efficacy  of the use  of this investigational  device  for abdominal fat  reduction.  This 
2.3 POTENTIAL  RISKS  AND  BENEFITS  
2.3.1  KNOWN  POTENTIAL  RISKS  
2.3.2  KNOWN  POTENTIAL  BENEFITS  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  7 of 32  
  
understanding may lead to optimization of the treatment with this device.  In addition, the subject may  
benefit  from  reduction  in unwanted adipocytes.  
 
 
The objective of this clinical study is to assess the safety and efficacy of using a 1060 nm diode laser for  
non-invasive fat reduction  of the  abdomen.  
 
Primary  objectives  
• To determine proportion of independent, blinded reviewers who correctly identify pre - 
treatment  baseline  images  and images  taken  at twelve  weeks  post -treatment  
Secondary  objectives  
• To determine the change in thickness of the adipose layer as measured by ultrasound at twelve  
weeks po st-treatment  as compared to  baseline  
• To determine the change in abdominal circumference at twelve weeks post -treatment as  
compared  to baseline  
• To assess subject satisfaction with treatment at twelve weeks using the 5 -Point Likert Subject  
Satisfaction  Scale  
Safety  
• Subject’s assessment of discomfort and pain post -treatment as measured by the Wong -Baker  
Faces  Pain  rating  scale.  
• Subjects  experiencing  a treatment -related  adverse  event  (AE).  
 
 
 
This is an open -label, baseline -controlled, evaluator -blind multi -center study evaluating one treatment  
with  a 1060  nm diode  laser  for non -invasive  fat reduction  of the abdomen.  
 
• Photographic evaluation by independent, blinded reviewers with correct identification of pre - 
treatment  baseline  images  when  compared  to post -treatment  images  taken  at twelve  weeks  
 
• To determine the change in thickness of the  adipose layer as measured by ultrasound at twelve  
weeks post -treatment  as compared to  baseline  
• To determine the change in abdominal circumference at twelve weeks post -treatment as  
compared  to baseline  
• To assess subject satisfaction with treatment at twelv e weeks using the 5 -Point Likert Subject  
Satisfaction  Scale  
 
Safety  Endpoints:  
• Report subject’s assessment of discomfort and pain as measured by the Wong -Baker Faces Pain  
rating  scale.  
• Report  subjects experiencing  a treatment -related  adverse  event  (AE).  
3 OBJECTIVES  AND  PURPOSE  
4 STUDY  DESIGN  AND  ENDPOINTS  
4.1 DESCRIPTION  OF THE  STUDY  DESIGN  
4.2.1  PRIMARY  ENDPOINTS  
4.2.2  SECONDARY  ENDPOINTS  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  8 of 32  
  
 
 
 
1. Able  to read,  understand  and voluntarily provide  written  informed  consent  . 
2. Healthy  male  or female,  ≥  18 years of  age seeking  treatment  for unwanted fat  in the abdomen.  
3. BMI score  is less than  30. 
4. Agree  to not  making  any major  changes  in their  diet or lifestyle  during  the course  of the study.  
5. Able  and willing  to comply  with  the treatment/follow -up schedule  and requirements.  
6. Women of child -bearing age are required to be using a reliable method of birth control at least 3  
months prior to study enrollment and for the duration of the study, and have a negative Urine  
Pregnancy  test at baseline.  
 
1. Pregna nt in the last 3 months, intending to become pregnant, postpartum or nursing in the last  
6 months.  
2. Any previous liposuction/lipo -sculpture or any type of surgical procedure in the treatment area  
in the past  12 months.  
3. History of immunosuppression/immune de ficiency disorders (including AIDS and HIV infection)  
or use of immunosuppressive  medications, 6  months  prior to and  during  the course  of the  study.  
4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive  
bleeding.  
5. Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants,  
thrombolytics  or anti-inflammatory  medications within  2 weeks  of treatment.  
6. Having a history of skin cancer or any other cancer in the areas to be treated, including presence  
of malignant  or pre -malignant  pigmented lesions.  
7. Having a permanent implant in the treatment area such as metal plates or an injected chemical  
substance  such  as silicone or  parenteral gold  therapy  (gold  sodium  thiomalate).  
8. Use of medicat ions,  herbs,  food  supplements,  and vitamins  known  to induce  photosensitivity  to 
light  exposure  at the wavelength  used  or history  of photosensitivity disorder.  
9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions  
including but not limited to open lacerations, abrasions, herpes sores, cold sores, active  
infections.  
10. Tattoos  in the treatment area.  
11. Poor  skin quality  (severe laxity).  
12. Abdominal  wall,  muscular  abnormality  or hernia  on physical  examination.  
13. Unst able weight  within  the last 6 months  (± 3% weight  change  in the prior  six months).  
14. Use of retinoids such as oral isotretinoin (Accutane ™) within the past six months or during  
course  of the study.  
15. Participation in another clinical study involving the same anatomical areas within the last 6  
months.  
16. History  of keloid  or hypertrophic  scar formation  or poor  wound  healing in  the treatment area.  
17. As per the investigator’s  discretion,  any physical  or mental  condition  which  may  make it  unsafe  
for the subject  to participate.  
5 STUDY  ENROLLMENT  AND  WITHDRAWAL  
5.1 PARTICIPANT  INCLUSION  CRITERIA  
5.2 PARTICIPANT  EXCLUSION  CRITERIA  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  9 of 32  
  
18. Unable or unlikely to refrain from sun exposure, artificial tanning, including the use of tanning  
booths,  prior  to (six weeks)  and during  the course  of the evaluation.  
 
 
Up to 50 subjects will be enrolled at up to 5 sites.  It is anticipated that it will take up to twelve months  
to complete the study.  Subjects requesting non -invasive lipolysis of the abdomen will be recruited  
primarily from the investigator’s clinic.  Any advertising campaigns and materials will be reviewed and  
approved by an institutional review board (IRB) before implementation.  Due to the duration of the  
study, subjects will be contacted by the investigative site on a regular b asis in order to enhance  
retention.  
 
 
 
Subjects are free to withdraw from participation in the study without prejudice at any time upon  
request.  In the event that a subject drops out of the study or is withdrawn from the study, the End of  
Study/Early Discontinuation CRF form should be completed. On the withdrawal page, the Investigator  
should  record  the date  of the withdrawal and  the reason  for withdrawal.  
 
Reasonable effort should be made to contact any subject lost to follow up during the course of the study  
in order to complete assessments and retrieve any outstanding data.  The records of subjects who  
terminate prior to completing the study will be retained a nd the reason for termination will be  
documented.  
 
An investigator  may  terminate  participation in  the study  if: 
 
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation  
occurs such that continued participation in the study would not be in the best interest of the  
subject.  
• The subject meets an exclusion criterion (either newly developed or not previously recognized)  
that precludes  further  study participation.  
 
 
Every effort will be made to continue follow -up of withdrawn or terminated subjects or subjects who  
discontinue the intervention but remain in the study for follow -up, especially for safety and efficacy  
study endpoi nts. Every effort will be made to conduct a final visit and undertake protocol -specified  
safety follow -up procedures to capture AEs, serious adverse events (SAEs), and unanticipated problems  
(UPs).  
 
 
The sponsor  may  suspend  or prematurely  terminate  this study  at an individual  investigation  site or the 
entire  study for significant  and documented  reasons.  
5.3 STRATEGIES  FOR RECRUITMENT  AND  RETENTION  
5.4 PARTICIPANT  WITHDRAWAL  OR TERMINATION  
5.4.1  REASONS  FOR WITHDRAWAL  OR TERMINATION  
5.4.2  HANDLING  OF PARTICIPANT  WITHDRAWALS  OR TERMINATION  
5.5 PREMATURE  TERMINATION  OR SUSPENSION  OF STUDY  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  10 of 32  
  
A principal  investigator  (PI), IRB, or regulatory  authority  may  suspend  or prematurely  terminate  
participation  in the study at the investigation  site for which  they are  responsible.  
 
If suspicion of an unacceptable risk to subjects arises during the study, or when so instructed by the IRB  
or regulatory authorities, the sponsor shall suspend the clinical investigation while the risk is assessed.  
The sponsor  shall  terminate  the study if  an unacceptable  risk is  confirmed.  
 
The sponsor  shall consider  terminating  or suspending  the participation of the investigation  site or 
investigator in the study if monitoring or auditing identifies serious or repeated deviations on the part of  
an investigator.  
 
If suspension or premature termination occurs, the terminating party shall justify its decision in w riting  
and promptly inform the other parties with whom they are in direct communication. The principal  
investigator and sponsor shall keep each other informed of any communication received from either the  
EC/IRB  or the regulatory  authority.  
 
If, for any reason,  the sponsor  suspends  or prematurely  terminates  the study  at the investigation  site,  the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the EC/IRB is  
notified,  either  by the principal  investigator  or by the sponsor.  If the suspension  or premature  termination  
was in the interest  of safety, the  sponsor shall  inform  all other  principal investigators.  
 
If suspension  or premature  termination  occurs,  
a) the sponsor  shall  remain  responsible  for providing  resources  to fulfil  the obligations  from  the 
protocol  and existing  agreements  for following  up the subjects  enrolled  in the  study, and  
b) the principal  investigator  or authorized  designee  shall  promptly  inform  the enrolled  subjects  at 
the investigation  site,  if appropriate  
 
In case of early termination, final study activities according to the protocol, including the follow -up visits  
and procedures to assess the safety and efficacy of the device will be conducted, regardless of the  
sponsor's  interest in the study.  Follow -up activities will be conducted so that device deficiencies can be  
identified,  and appropriate  safety  measures  can be implemented.  
 
At the completion  or termination  of the study,  the Investigator  will return  all remaining  clinical  supplies  
to Sponsor  along  with a  copy of  the device  supply  and inventory  records.  
 
Circumstances  that may warrant  termination  or suspension  include,  but are  not limited  to: 
• Determination of unexpected, significant, or unacceptable risk to participants (examples of  
findings that might trigger a safety review are the number of SAEs overall, the number of  
occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events – 
refer  to section  8.5 STUDY  HALTING RULES).  
• Demonstration  of performance that  would  warrant  stopping  
• Insufficient  compliance  to protocol  requirements  
• Data  that are not sufficiently  complete  and/or  evaluable  
• Determination  of futility  
Study may resume once concerns about safety, protocol compliance, data quality and the like as the  
case  may  be are  addressed  and satisfy  the sponsor, IRB  and/or  regulatory  authorities.  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  11 of 32  
  
 
 
 
 
 
 
The Venus Bliss ™ investigational device will be shipped to the investigative site directly from the  
sponsor.  Training on the use of the device will be provided by the sponsor.  The investigative site will  
not perform any treatments until all regulatory and IRB approvals are in place and the site has received  
training  for both devices and  the study.  
 
 
The Venus BLISS ™ investigational device is a 1060nm diode laser system intended for non -invasive  
lipolysis of the abdomen in  individuals with a Body Mass Index (BMI) of less than 30.  The device consists  
of a console, four laser applicators and a belt that secures the laser applicators in place securely to the  
subject’s selected treatment area.  Each applicator includes contact t issue cooling and has an active area  
of 60mm  x 60mm.  
 
The clinician is able to control the settings from the graphical user interface (GUI) display on the main  
console.  The available settings for this  applicator is:  
 
• Optical power up to 1.4 W/cm2 at 1060nm  
Treatment  time  is 25 minutes.  
 
The device and applicators will be shipped to the site by the sponsor.  Traceability shall be achieved  
during and after the clinical investigation by assignment  of serial numbers to device and applicators and  
accounting  for the  device  and applicators returned  to the sponsor by each site.  
 
The device will be labeled as an investigational device and will require protocol and device training from  
the sponsor.  
 
 
 
 
The following  procedures  and evaluations  will be done  as part of the study:  
Demographics  
Medical  / surgical  history  
6 STUDY  DEVICE  
6.1 STUDY  DEVICE  AND  CONTROL  DESCRIPTION  
6.1.1  ACQUISITION  
6.1.2  DEVICE  SPECIFIC  CONSIDERATIONS  
6.2 STUDY  DEVICE  ACCOUNTABILITY  PROCEDURES  
7 STUDY  PROCEDURES  AND  SCHEDULE  
7.1 STUDY  PROCEDURES/EVALUATIONS  
7.1.1  STUDY  SPECIFIC  PROCEDURES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  12 of 32  
  
Physical examination (as per site’s standard of care)  
Assessment  of eligibility  
Urine pregnancy test for women of child bearing potential (visit 1 only)  
Treatment  area  marking  
Abdominal circumference measurements  
Photographs (visit  1, visit 2 and visit 3) 
Ultrasound  subcutaneous  fat (visit  1, visit 2 and  visit3)  
Administration of a questionnaires/scales for patient -reported outcomes (visit 1 and visit 3 only)  
Adverse  event recording  
Concomitant  medications  
 
 
 
For women of child -bearing potential, urine pregnancy test to be performed according to local site  
standards within 24 hours of study intervention.  Results must be available prior to adm inistration of the  
treatment.  
 
 
 
Screening  Visit  
 
If the subject meets the preliminary study criteria the study doctor, and/or his/her designee, will obtain  
an informed consent from the subject, clearly indicating h is/her understanding of the requirements and  
possible risks involved with study participation and other applicable treatment options.  Subjects will  
receive a unique identifying number that will be composed of a two -digit site number and a three digit  
subje ct number in sequence.  This unique identifier will be used throughout the entire study and will be  
entered  in the subject's  case  report form  (CRF)  and for each  treatment.  
 
During  screening  visit,  the study  investigator,  and/or  his/her  designee,  will assess  the subject  for eligibility  
to participate  in the clinical  study  using  the inclusion/exclusion  criteria.  A urine  sample  for the pregnancy  
test will be obtained for female subjects of child -bearing potential.  During screening, the study doctor  will 
review the subject's medical/surgical history and examine the target treatment areas to ensure they  meet 
the study criteria.  
 
Subjects  will be instructed  to avoid  sun exposure  of the target  treatment  areas  for at least  six weeks  before  
treatment and t o use broad spectrum sunscreen of no less than 30 SPF daily, replenishing it as often as  
needed throughout the course of the study and for six weeks after the treatment.  In addition, tanning is  
to be strictly  avoided.  Subjects  should  not receive  any treatment  with  a laser  or other  devices  in the study  
treatment  area  throughout  the course  of this study and  follow -up examinations.  
 
The investigator will ask women of child -bearing potential for the date of their last period.  The 
investigator  shall  inquir e about  the form  of contraceptive  they  use to confirm  they  meet  the inclusion  
criteria.  
7.2 LABORATORY  PROCEDURES/EVALUATIONS  
7.2.1  CLINICAL  LABORATORY  EVALUATIONS  
7.3 STUDY  SCHEDULE  
7.3.1  SCREENING  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  13 of 32  
  
The subject will complete screening and the treatment will be scheduled.  Treatment may be performed on the  
day the subject  was enrolled  if the results  of the urine  pregnancy  test are available  (and negative)  and the subject  
has avoided sun exposure  of the target treatment area  for at  least  six weeks.  
 
 
Enrollment/Baseline/Treatment Visit (Visit 1 – Day 0)  
Pre-Treatment  
The investigator will confirm that the subject continues to meet the inclusion and none of the exclusion  
criteria.  Adverse events, weight and any changes to concomitant medications will be recorded.  The 
subject  will complete  the modified  Simple  Lifestyle Indicator  Questionnaire (SLIQ).  
 
The location and size of the treatment area will be left to the principal investigator’s judgement based  
on his/her assessment of individual subject requirements for treatment.  The defined abdomina l 
treatment area will be marked with a semi -permanent pigment using a treatment template as per the  
sponsor’s instructions.  Photographs of the marked treatment area followed by ultrasound  
measurements of the marked treatment area will be made as per the in structions supplied by the  
sponsor.  Measurement of the abdominal circumference will be made with the sponsor supplied tape  
measure using  the marked  boundaries  as a guide  for replication.  
 
Treatment  
Protective eye goggles will be worn by both the patient and site staff performing the treatment for the  
duration  of the treatment  session.  
 
Based on the mild nature of treatment, anesthesia is not required. The treatment procedure should  
include positioning of the patient in a manner that enables access to the target treatment anatomical  
site.  
 
The belt will be positioned on the subject as per the marked treatment template.  Laser applicators will  
be secured in place by the belt with the areas treated for up to 25 minutes.  The laser energy will be  
delivered  to the  area  while  cooling  is administered  to the skin  surface to increase  subject  comfort.  
Treatment will continue until the total treatment area has been treated.  The subject will receive one  
treatment  session  only.  
 
The assessment of discomfort/ pain during the treatment procedure will be assessed using the Wong - 
Baker  Faces  Pain  rating  scale  with  treatment  parameters  adjusted  according  to patient’s  comfort  level.  
 
Post  Treatment  
 
Assessment  
 
The investigator will examine the treated areas and report immediate response (pain during treatment,  
hemorrhage, burn, erythema, edema, purpura) using a 5 point scale: 1=none; 2=trace; 3=moderate;  
4=marked;  5=severe.  
 
The assessment of discomfort/pain based on the subject’s completion of the 10 cm viusla p ain scale  
should  also be documented  immediately after  treatment.  
7.3.2  ENROLLMENT/BASELINE  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  14 of 32  
  
The normal response to this treatment is transient tenderness, edema and/or induration in the treated  
area which should resolve within one to two weeks.  If any other side effects occur or persist for longer  
than  expected,  they  must  be recorded  in the adverse event  (AE) section  of the case report  form (CRF).  
 
For post -treatment cooling and/or discomfort, cold packs can be applied to treatment area if needed  
with  acetaminophe n at recommended  doses  used to  alleviate  pain  as needed.  
 
During the day following treatment, care should be taken to prevent any mechanical or thermal damage  
to the treated sites:  avoid hot baths, massage, contact sports, swimming, etc.  The treated areas should  
be kept clean to avoid contamination or infection.  The subject should be reminded to not make any  
major  changes  in their diet  or lifestyle  during  the course of  the study.  
 
Subjects will  be discharged  from  the clinic  and will be  scheduled to  return  for the six week  assessment.  
 
 
Visit  2, Week 6  (± 3 days)  
 
Subjects will return to the clinic six weeks after the treatment.  Adverse events, weight and any changes  
to concomitant  medications will be  recorded.  
 
Measurement of the abdominal circumference will be made with the sponsor supplied tape measure  
using  the marked boundaries  as a guide  for replication.  
 
Photographs of the marked treatment area followed by ultrasound measurements of the marked  
treatment  area will be  made  as per  the instructions supplied by the  sponsor.  
 
Subjects will be discharged from the clinic and will be scheduled to return for the Twelve week (Final)  
assessment.  
 
 
Visit  3, Week  12 (± 7 days)  
Subjects may return to the clinic twelve weeks after the treatment.  Adverse events, weight and any  
changes to  concomitant  medications  will be  recorded.  
 
Subjects will be asked to complete the lifestyle, 5 -point Likert subject satisfaction and treatment  
evaluation quest ionnaires. Measurement of the abdominal circumference will be made with the  
sponsor  supplied tape  measure  using  the marked  boundaries  as a guide  for replication.  
 
Photographs of the marked treatment area followed by ultrasound measurements of the marked  
treatment  area  will be  made  as per  the instructions supplied  by the  sponsor.  
 
The End of Study form will be completed and subjects will be discharged from the clinic and terminated  
from  the study.  
 
The PI will record all reportable events with start dates occurring any time after informed consent is  
obtained  until  7 (for non-serious  AEs)  or 30 days  (for SAEs)  after  the last day  of study  participation.  
7.3.3  FOLLOW -UP 1 
7.3.4  FINAL  STUDY  VISIT  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  15 of 32  
  
 
 
Subjects who terminate the study early for whatever reason, will be asked to provide a reason for their  
early  termination.  Adverse  events and  the reason  for early  termination  will be  recorded.  
 
 
If an unscheduled visit occurs, the reason for the unscheduled visit will be documented.  If the  
unscheduled  visit is the result of an  adverse  event, the  event  will be  recorded  on the adverse  event  CRF.  
 
 
 
 
 
 
 
 
 
 
 
Procedures  
Screening  
(-6 weeks)  
Enrollment/Treatment  
(Visit  1, Day 0) 
Follow -up 1 
Visit  2, Week  6 (±3 days)  
Follow -up 2 
(Visit  3, Week  12 (±7 days)  
Informed  consent  X    
Inclusion/exclusion  criteria  X X   
Demographics  X    
Medical  history  X    
Physical  exam  X    
Weight   X X X 
Urine  pregnancy  testa X    
Lifestyle  Indicator  Questionnaire   X  X 
Abdominal  circumference   X X X 
Photographs   X X X 
Ultrasound  subcutaneous  fat  X X X 
Administer  Treatment   X   
Discomfort/Pain  Visual  Pain  Scale   X   
PI immediate  response   X   
Blinded  reviewers GAIS   X  X 
Subject  satisfaction  questionnaire     X 
Treatment  evaluation  questionnaire      
Concomitant  medication  X X X X 
Adverse  event  evaluation   X X X 
 
 
 
N/A 
7.3.5  EARLY  TERMINATION  VISIT  
7.3.6  UNSCHEDULED  VISIT  
7.3.6  SCHEDULE  OF EVENTS  TABLE  
7.4 JUSTIFICATION  FOR SENSITIVE  PROCEDURES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  16 of 32  
  
 
 
All concomitant prescription medications taken during study participation will be recorded on the case  
report forms (CRFs).  For this protocol, a prescription medication is defined as a medication that can be  
prescribed only by a properly authorized/licensed clinician.  Other medications to be reported in the CRF  
are concomitant  over -the-counter  medications and  non-prescription  medic ations.  
 
 
The use of immunosuppressive medications, antiplatelet medications, thrombolytics, anti -inflammatory  
medicatons and anticoagulant medications is to be avoided. Herbal supplements, perfumes , cosmetics  
and/or medications that may affect sensitivity to light are prohibited.  The use of Accutane ™ 
(Isotretinoin)  within  the past  six months  is also strictly  prohibited.  
 
 
None.  
 
 
In the event that the subject experiences pain, the principal investigator may prescribe any analgesic  
deemed appropriate to the level of pain.  If a subject experiences any first, second or third degree burn  
or pain  beyond  narcotics, then the  following  procedure  will be implemented:  
Immediate triage and treatment of the patient shall be determined by the treating physician and based  
upon  severity and  type  of burn  identified.  
 
The event will be repo rted to the study Director within 24 hours of occurrence. If the event meets the  
criteria  of a SAE, then it  must  be reported  on the SAE form.  
 
A copy of the patient chart and treatment parameters are to be forwarded to the study Director within  
24 hours.  
 
The study Director will be responsible for issuing a written report to the company and the IRB Chairman  
no later than  7 days from  the incident.  
 
Long  term follow up  and care  shall  continue at  the discretion  of the treating  physician.  
 
All patients experiencing a complication of the device will be followed a minimum of 2 years following  
the initial  injury.  Longer  care and  observation  will be at the discretion  of the treating  physician.  
 
All minor complications such as appearance or altered sensation,  except for pain, can be reported within  
30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study  
Director  and shared  with the  company  and IRB chairman.  
7.5 CONCOMITANT  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.6 PROHIBITED  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.7 PROPHYLACTIC  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
7.8 RESCUE  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  17 of 32  
  
 
 
 
In addition to spontaneous reports of adverse events, subjects will complete a 10 cm discomfort/pain  
visual pain scale and the principal investigator will examine the treated area and report immediate  
response.  
 
 
Adverse event means any untoward medical occurrence associated with the use of an intervention in  
humans,  whether  or not  considered intervention -related (21  CFR 312.32  (a)). 
 
 
NOTE:  The term serious  is not synonymous  with  severity,  which  may be used  to describe the intensity  of 
an event experienced by the subject). An AE that does not meet any of the below criteria will be  
classified  as non-serious.  
 
A serious  AE is  any event  that:  
• Results in,  or contributes  to a death;  
• Is immediately  life threatening  (injury or  illness);  
• Results  in hospitalization,  or prolongs  an existing  hospitalization;  
• Results in permanent impairment of body structure or function, or in persistent or significant  
disability/incapacity;  
• Results in an injury that requires m edical intervention to prevent permanent impairment of  
body  structure  or function;  
• Is a device malfunction or deterioration in the characteristics and/or performance of the device  
that results in death or  serious deterioration  in health;  
• Is a device malfun ction or deterioration in the characteristics and/or performance of the device  
that,  if it were  to occur  again,  could  result in  death  or serious deterioration  in health;  
• Results  in a congenital anomaly  or birth defect.  
• Is any medically significant injury, event or experience that requires medical/surgical  
intervention  to prevent  one of the outcomes  listed  above;  
• Results in end  organ toxicity, including hematological, renal, cardiovascular, hepatic,  
gastrointestinal,  and central nervous s ystem  events;  
 
 
This definition includes an unanticipated adverse device effect, any serious adverse effect on health or  
safety or any life -threatening problem or death caused by, or associated with, a device, if that effect,  
problem, or death was not previously identified in nature, severity, or degree of incidence in the  
investigational plan or application (including a supplementary plan or application), or any other  
unanticipated serious problem assoc iated with a device that relates to the rights, safety, or welfare of  
subjects (21  CFR 812.3(s)).  
8 ASSESSMENT  OF SAFETY  
8.1 SPECIFICATION  OF SAFETY  PARAMETERS  
8.1.1  DEFINITION  OF ADVERSE  EVENTS  (AE)  
8.1.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE)  
8.1.3  DEFINITION  OF UNANTICIPATED  PROBLEMS  (UP)  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  18 of 32  
  
 
 
 
For AEs not included in the protocol defined grading system, the following guidelines will be used to  
describe severity.  
 
• Mild  – Events  require  minimal  or no treatment  and do not  interfere  with  the participant’s daily  
activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic  
measures.  Moderate  events  may cause  some interference  with  functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug  
therapy or other treatment. Severe events are usually potentially life -threatening or  
incapacitating.  
 
 
The clinician’s assessment of an AE's relationship  to the study agent is part of the documentation  
process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt  
as to whether a clinical observation is an AE, the event should be reported. All AEs must have th eir 
relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To  
help  assess,  the following  guidelines  are used.  
 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that  
the study agent caused the AE, or there is a temporal relationship between the study agent and  
event. Reasonable possibility means that there is evidence to suggest a causal relationship  
between the  study  agent and  the AE. 
• Not Related – There is not a reasonable possibility that the administration of the study agent  
caused the event, there is no temporal relationship between the study agent and event onset,  
or an alternate  etiology has been  established.  
 
 
Expected adverse reactions  are AEs that are common and known to occur for the study agent being  
studied.  Expected adverse events of the treatment include transient tenderness, erythema, edema,  
and/or  induration  in the treated area lasting  from  one to three  weeks after the treatment . 
The device has a contact tissue cooling system in place during the procedure to minimize thermal  
discomfort and prevent damage to the treatment area.  Expected adverse events related to the contact  
cooling  include  tingling,  itching, decreased  sensation,  numbness,  erythema  and tenderness.  
 
An AE or suspected adverse reaction is considered "unexpected" if it is not known to occur for the study  
treatment  being  studied  and at the  specificity  or severity  that has been  observed.  
 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and  
interviews  of a study  participant  presenting  for medical  care,  or upon  review  by a study  monitor.  All AEs 
8.2 CLASSIFICATION  OF AN ADVERSE  EVENT  
8.2.1  SEVERITY  OF EVENT  
8.2.2  RELATIONSHIP  TO STUDY  AGENT  
8.2.3  EXPECTEDNESS  
8.3 TIME  PERIOD  AND FREQUENCY  FOR EVENT  ASSESSMENT  AND  FOLLOW -UP 
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  19 of 32  
  
including local and systemic reactions not meeting the criteria for SAEs will be captured on the  
appropriate CRF. Information to be collected includes event description, time of onset, clinician’s  
assessment of severity, relationship to study product (assessed only by those with the training and  
authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while  
on study must be documented appropriately regardless of relationship. All AEs will be fol lowed to  
adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as  
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any  
time during the st udy, it will be recorded as an AE. UPs will be recorded in the data collection system  
throughout  the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event  
at each level of severity to be performed. AEs characterized as intermittent require documentation of  
onset  and duration  of each  episode.  
 
The PI will record all reportable events with start dates occurring any time after informed consent is  
obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. At  
each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events  
will be followed  for outcome  information  until resolution  or stabilization.  
 
 
 
All AEs will be recorded on the appropriate CRF and will include information about the start and stop  
dates, severity and relatedness. There should be an attempt to report a “diagnosis” rather than the  
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a  
diagnosis should be reported only if, in the Investigator’s judgment, it is relatively certain (i.e., definite  
or possible). Otherwise individual signs, sym ptoms and abnormal laboratory values should be reported  
as distinct adverse  events.  
 
 
All serious  AE, whether  or not deemed  expected  or device related,  must  be reported  to the  sponsor’s  
clinical  research  department immediately  or within  24 hours  by telephone (see  contact  details  below).  
 
Name:  Andrea Biro, Clinical Research Manager  
Phone:  888-907-0115  ext. 132 
Email:  abiro@venusconcept.com  
Address:  255 Consumers  Road,  #110,  Toronto,  Ontario,  Canada,  M2J 1R4 
 
A written report prepared by the Principal Investigator must follow within seven working days to the  
clinical  monitor and  should  include a full description  of the event and  sequence.  
 
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and  
submit to the study sponsor and to the reviewing IRB as soon as possible, but in no event l ater than 10  
working days after the investigator first learns of the effect. The study sponsor contact information is  
provided  in Section  1, Key  Roles.  The study sponsor is  responsible  for conducting  an evaluation  of an 
8.4 REPORTI NG PROCEDURES  
8.4.1  ADVERSE  EVENT  REPORTING  
8.4.2  SERIOUS  ADVERSE  EVENT  REPORTING  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  20 of 32  
  
unanticipated adverse  device effect and shall report the results of such evaluation to Health Canada, the  
FDA or local  regulatory  agency  and to  all reviewing  IRBs  and participating investigators  within  10 
working days after the sponsor first receives notice of the effect. Thereafter the sponsor shall submit  
such additional reports concerning the effect as Health Canada, the FDA or local regulatory agency  
requests.  
 
 
Incidents or events that meet the criteria for UPs require t he creation and completion of an UP report  
form. It is the site investigator’s responsibility to report UPs to their IRB and to the study sponsor. The  
UP report  will include  the following  information:  
 
Protocol  identifying  information:  protocol  title and number,  PI’s name,  and the IRB project number;  
 
• A detailed  description  of the event,  incident,  experience,  or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome  
represents  an UP; 
• A description of any c hanges to the protocol or other corrective actions that have been taken or  
are proposed in  response  to the UP. 
 
An investigator shall submit to the sponsor and to the reviewing IRB a report of any unanticipated  
adverse device effect occurring during an inv estigation as soon as possible, but in no event later than 10  
working days after the investigator first learns of the effect (21 CFR 812.150(a)(1)), A sponsor who  
conducts  an evaluation  of an  unanticipated  adverse device  effect  under 812.46(b)  shall  report  the 
results of such evaluation to Health Canada, the FDA or local regulatory agency and to all reviewing IRB's  
and participating investigators within 10 working days after the sponsor first receives notice of the  
effect. Thereafter the sponsor shall  submit such additional reports concerning the effect as FDA (21 CFR  
812.150(b)(1))  or local regulatory agency  requests.  
 
 
If a subject becomes pregnant during the course of the study, the subject will be terminated from the  
study. The pregnancy will be immediately reported to the sponsor on the Notification of Subject or  
Partner Pregnancy form and to the IRB using the same reporting timelines as a SAE. The investigator will  
follow the pregnancy until completion and will repo rt the outcome of the pregnancy to the sponsor on  
the Notification  of Subject  or Partner  Pregnancy  Outcome form  and the IRB within  10 business days.  
 
 
The study may be halted at any time by the sponsor, the IRB, Health Canada, the FDA or local regulatory  
agencies due to safety concerns.  Examples of findings that might trigger a safety review are the number  
of SAEs overall, the number of occurrences of a particular type of SAE, severe AEs/reactions, or  
increased frequency  of events. If the study is halted, the sponsor will immediately notify all  
investigational  sites,  the IRB(s), Health  Canada,  the FDA  or local  regulatory  agencies.  
 
 
Independent oversight is an important component to ensure human subjects' protection.  Safety  
oversight  will be  under  the direction  of the sponsor and a medical  monitor.  
8.4.3  UNANTICIPATED  PROBLEM  REPORTING  
8.4.4  REPORTING  OF PREGNANCY  
8.5 STUDY  HALTING  RULES  
8.6 SAFETY  OVERSIGHT  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  21 of 32  
  
 
 
Clinical site monitoring is conducted to ensure that the rights and well -being of human subjects are  
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of  
the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with  
applicable  regulatory  requirement(s).  
 
• Mon itoring  for this study  will be performed  by the sponsor  or designate.  
• On-site monitoring will occur within 10 weeks of first enrolled subject and will occur at a  
frequency  described in  the Monitoring  Plan.  
• Variables  to be  monitored  will be described in  the Monitoring  Plan.  
• The Study Director or designate will be provided copies of monitoring reports within 15 business  
days  of visit.  
 
 
 
The Statistical and Analytical Plans (SAP) may be revised during the study to accommodate Clinical Trial  
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data  
that affect planned analyses.  If revised, a formal SAP will be completed and issued prior to database  
lock and unblinding  of the  study data . 
 
 
The null and alternative hypotheses for  the study’s  primary,  key secondary  and safety  endpoints  are; 
 
• Primary  Efficacy  Endpoints:  Statistical  hypothesis  will not be applied  in the analysis  of the study’s  
primary  endpoint  
 
• Secondary  Efficacy  Endpoint(s):  
o Null Hypothesis  (Ho: µd = µpost  – µbaseline  = 0) – There  is no change  in thickness  of the adipose  
layer as measured by ultrasound (US) at twelve weeks post -treatment as compared to  
baseline.  
 
Alternative Hypothesis (Ha: µd = µpost – µbaseline ≠ 0) – There is a change in thickness of the  
adipose  layer  as measured  by ultrasound  (US)  at twelve  weeks  post -treatment  as 
compared  to baseline.  The efficacy  endpoint  to treatment  will be defined  by reduction  in 
abdominal fat determined by decrease in thickness of the adipose layer as measured by  
ultrasound  (US)  at twelve  weeks  post -treatment  as compared to  baseline.  
 
o Null Hypothesis  (Ho: µd = µpost  – µbaseline  = 0) – There  is no change  in abdominal  
circumference  at twelve  weeks  post -treatment  as compared  to baseline.  
 
Alternative Hypothesis (Ha: µd = µpost  – µbaseline  ≠ 0) – There is a change in abdominal  
circumference  at twelve  weeks post -treatment  as compared  to baseline.  The change will  
9 CLINICAL  MONITORING  
10 STATISTICAL  CONSIDERATIONS  
10.1  STATISTICAL  AND  ANALYTICAL  PLANS  
10.2  STATISTICAL  HYPOTHESES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  22 of 32  
  
be defined  by reduction  in abdominal  circumference  at twelve  weeks  post -treatment  as 
compared  to baseline.  
 
o Null Hypothesis (Ho: µd = µpost  – µpre = 0) – There  is no satisfaction  with the  treatment  at 
twelve weeks using the 5 -Point Likert Subject Satisfaction Scale as assessed by the  
subjects.  
 
Alternative  Hypothesis (Ha: µd = µpost  – µpre ≠ 0) – There  is satisfaction  with  the treatment  
at twelve weeks using the 5 -Point Likert Subject Satisfaction Scale as assessed by the  
subjects.  
 
• Safety  Endpoint:  Statistical  hypothesis  will not be used  in the analysis  of the study’s  safety  
endpoint.  
 
 
The Intention -to-Treat  Analysis  Dataset  will be used;  efficacy  and safety  analyses  will be carried  out on all 
subjects  who  underwent  Venus Bliss ™ treatment.  
 
 
 
This is an open -label, baseline -controlled, evaluator -blind multi -center study evaluating one treatment  
with  a 1060  nm diode  laser  for non -invasive  fat reduction  of the abdomen.  
 
All summary tables for quantitative parameters will display mean, standard deviation, median, range  
(minimum and maximum), percentages as well as number of missing data (if relevant).  All summary  
tables for qualitative parameters will display counts, percentages and number of missing data if  
relevant. Baseline data are defined as the last photograph and measurement performed before the first  
treatment  on Visit  1. 
 
All statistical  tests  will be two-sided,  where  applicable.  The level  of statistical  significance  for 
effectiveness analyses is 5% (α = 0.05) for all tests of differences. Where appropriate, t -test and/or two - 
proportion z -test will be used to compare outcome at twelve weeks post -treatment as compared to  
baseline. This test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will  
establish that:  
 
• The two-sided  95%  confidence interval  for the difference between  the means  excludes  zero.  
• The two means  are statistically  significantly  different  at the 5% level  (P < 0.05)  two-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval, and/or One - 
way ANOVA and/or descriptive statistical tools may be used to determine the performance of the  
treatment.  
10.3  ANALYSIS  DATASETS  
10.4  DESCRIPTION  OF STATISTICAL  METHODS  
10.4.1  GENERAL  APPROACH  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  23 of 32  
  
In order  to accommodate  imbalances  of some  baseline  of scores  or measurements,  covariate  adjus tment  
analysis may be performed in SAP to estimate adjusted treatment effects for the primary endpoint  
analysis.  
 
The assumption for the statistical test is that variables are normally distributed within study group and  
the variation of scores or measureme nts at twelve weeks post -treatment as compared to baseline is not  
reliably different.  
 
The safety analysis will be done by analyzing spontaneous reports of adverse events (AE), subjects’  
completed 10 cm discomfort/pain visual pain scale and immediate respo nse reports by the principal  
investigator from his/her observation/examination of the treated area.  Appropriate Medical Dictionary  
for Regulatory  Activities  (MedDRA)  code  will be used  to describe  all spontaneously  reported  or other  study  
related  adverse  events.  
 
 
The following  will be consider  for the analysis  primary  endpoints:  
The results of each Blinded Reviewer’s evaluation of photographs taken at three and six moth compared  
to baseline will be analyzed and the results will be reported as a % of the correctly identified post  
treatment  photographs  chosen  per Blinded  Reviewer.  An average  of the % of the correctly  identified  post  
treatment  photographs chosen by  Blinded  Reviewer  will be calculated  and used  to determine  
 
Bar, pie charts or graphs indicating percentages of the correctly identified post treatment photographs  
chosen  by Blinded Reviewer may  also be used to  analyse  efficacy.  
 
The efficacy endpoint to treatment will be defined by an average of the 80% of the correctly identified  
post  treatment  photographs  chosen  by Blinded  Reviewer  This will be used  to determine  if the study  meets  
the primary  endpoint  expectation.  
 
The % of the correctly identified post treatment photographs chosen by  Blinded Reviewer of all subjects  
who received at least one treatment of Venus Bliss ™ and for whom at least one valid post -baseline  
assessment were obtained will be analysed for these primary endpoints. Mutiple imputation  method or  
modelling  of available  data  may be used for  missing  data  as appropriate.  
 
 
For the analysis of changes in change in thickness of the adipose layer, abdominal circumference and  
subjects’  assessment  of satisfaction  with  the treatment  secondary  endpoints  the following  analysis  will be 
considered:  
 
Summary tables of changes in thickness of the adipose layer measured by ultrasound (US), abdominal  
circumference, and subjects’ assessment of satisfaction at tw elve weeks post -treatment as compared to  
baseline will  be displayed  as mean  difference, standard  deviation  and standard  error.  
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages  
and/or proportions of changes in thickness of the adipose layer measured by ultrasound (US), abdominal  
circumference, and subjects’ assessment of satisfaction at twelve weeks post -treatment as compared to  
baseline will  be used  where  applicable  to analyse  efficacy.  
10.4.2  ANALYSIS  OF THE  PRIMARY  ENDPOINTS  
10.4.3  ANALYSIS  OF THE  SECONDARY  ENDPOINTS  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  24 of 32  
  
All statistical tests that will be two -sided. The level of statistical significance for effectiveness analyses is  
5% (α = 0.05)  for all tests  of differences.  Where  appropriate,  two-proportion  z-test will be used  to compare  
the diff erences between of changes in thickness of the adipose layer measured by ultrasound (US),  
abdominal circumference, and subjects’ assessment of satisfaction at twelve weeks post -treatment as  
compared  to baseline. Analysis  of Covariance (ANCOVA)  may also be  used  where  appropriate.  
Change in thickness of the adipose layer measured by ultrasound (US), abdominal circumference, and  
subjects’  assessment  of satisfaction  assessments  at twelve  weeks  post -treatment  as compared  to baseline  
of all subjects who received at least one treatment of Venus Bliss ™ and for whom at least one valid post - 
baseline assessment were obtained will be analysed for these secondary endpoints. Mutiple imputation  
method  or modelling  of available  data  may  be used for  missing  data as  appropriate.  
 
 
The safety analysis will be done by analyzing spontaneous reports of adverse events (AE), subjects’  
completed 10 cm discomfort/pain visual pain scale and a response questionnaire as well as analysis of  
immediate response reports by the principal investigator from his/her observation/examination of the  
treated area. Appropriate Medical Dictionary for Regulatory Activities (MedDRA) code will be used to  
describe all  spontaneously  reported  or other study  related adverse  events.  
 
Summaries  of spontaneously reported  or other  study  related  adverse events  will be presented  as: 
 
o Number  (%) of subjects  with  any AE,  
o Number  (%) of subjects  with  any serious  adverse events  (SAE),  
o Number  (%) of subjects  permanently  withdrawn  from  treatment  due to  AE 
Summaries of analysis of immediate response reports by the principal investigator examination will be  
displayed  on a bar or pie  chart as;  
 
o the overall frequency of subjects with each event (pain during treatme nt, hemorrhage, burn,  
erythema,  edema,  purpura)  
o Frequency of subjects with specific severity/intensity for each event using a 5 points scale:  
1=none;  2=trace;  3=moderate;  4=marked;  5=severe  
o The overall percentage or proportion of subject observed with mark ed or severe intensity of any  
event will be calculated and compared to those with none, trace or moderate severity/intensity  
with the  aid of a bar  or pie  chart.  
 
The following will be considered for the analysis of 10 cm discomfort/pain visual pain scale scores  safety  
data:  
 
A summary table of the 10 cm discomfort/pain visual pain scale scores post treatment will be displayed  
as mean difference, standard deviation and standard error.  The 10 cm discomfort/pain visual pain scale  is 
a 11 -level  (0 to 10) ordinal  scale  tool for assessing pain.  
 
The overall  percentage  or proportion  of subject  that recorded  marked  or severe  post  treatment  
discomfort/pain visual pain scale scores may be calculated and compared to those with none, trace, low  
or moderate  discom fort/pain using a bar  or pie chart.  
10.4.5  SAFETY  ANALYSIS  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  25 of 32  
  
 
 
Adherence to the protocol will be assessed by calculating the number or (%) subjects’ data for each  
endpoint assessment that is not provided in subjects Case Report Forms. This will be further analyzed as  
per frequency of each endpoint data that is not available due to loss to follow -up, discontinuation of the  
intervention  or any  other  reason.  
 
 
Subjects baseline measurements and scores of all applicable endpoints will be compared using  
descriptive statistics such as mean score, standard deviation, standard error, range and graphical  
presentations.  
 
 
No interim analysis  is planned.  
 
 
There  will be no interim  analysis during  this study.  However,  this study  may  be temporarily  suspended  or 
prematurely  terminated  if there  is sufficient reasonable cause  as per section  5.5 and 8.5. 
 
 
There will be no interim analysis during this study. However, this study may be temporarily suspended  
or prematurely  terminated  if there is  sufficient reasonable  cause  as per section  5.5 and 8.5. 
 
 
Not applicable.  Primary or secondary endpoints may be analyzed based on age, sex, race/ethnicity or  
other  demographic characteristic(s).  
 
 
Not applicable . 
 
 
Individual  participant data  will be listed by  measure  and time  point  as appendix  to the study  report.  
 
 
Not applicable.  
 
 
The change in thickness of the adipose layer as measured by ultrasound (US) at twelve weeks post - 
treatment as compared to baseline secondary endpoint outcome measures was used to calculate the  
study  sample size.  
10.4.6  ADHERENCE  AND  RETENTION  ANALYSES  
10.4.7  BASELINE  DESCRIPTIVE  STATISTICS  
10.4.8  PLANNED  INTERIM  ANALYSES  
10.4.8.1  
 SAFETY  REVIEW  
10.4.8.2  
 EFFICACY  REVIEW  
10.4.9    ADDITIONAL  SUB-GROUP  ANALYSES  
10.4.10  
 MULTIPLE  COMPARISON/  MULTIPLICITY  
10.4.11  
 TABULATION  OF INDIVIDUAL  RESPONSE  DATA  
10.4.12  
 EXPLORATORY  ANALYSES  
10.5  SAMPLE  SIZE  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  26 of 32  
  
Sample  size calculation  using secondary  endpoint  outcome  measure;  
 
• Null and alternate  hypotheses:  
Null Hypothesis  (Ho: µd = µpost  – µbaseline  = 0) – There  is no change  in thickness  of the adipose  
layer as measured by ultrasound (US) at twelve weeks post -treatment as compared to  
baseline.  
 
Alternative Hypothesis (Ha: µd = µpost – µbaseline ≠ 0) – There is a change in thickness of the  
adipose  layer  as measured  by ultrasound  (US)  at twelve  weeks  post -treatment  as 
compared  to baseline.  The efficacy  endpoint  to treatment  will be defined  by reduction  in 
abdominal fat determined by decrease in thickness of the adipose layer as measured by  
ultrasound  (US)  at twelve  weeks  post -treatment  as compared to baseline.  
Expected reduction in abdominal fat of 2.65 + 1.41 obtained from a similar study (,Ba ss LS 
et al) will be  used  to determine  the sample  size.  
• In view  of the nature  of this study  in regard  to number  of visits,  we make  provision  for 10%  study  
drop  out, withdrawal  or loss to  follow -up. 
• 2- Tailed  Sample  Size calculation  formula  for two Samples  was used  in the table  below:  
 
(1-β), Desired  Power  0.8 
α, Level  of Significance  0.05  
μd, expected  reduction  in abdominal  fat measured  from  
baseline  to 3 month  post  treatment  visit under  Ha  
2.65  
σ, Standard  Deviation  (obtained  from  a study)  1.41  
Z1-α/2 1.96  
Z1-β, (for 80%)  0.84  
Estimated  Sample  Size 40 
Estimated  Sample  Size of each  equal  group  + 10%  drop  out 44 
Conclusion: The estimated sample size for the study and the additional 10% provision for drop out (44 
subjects) obtained from the secondary endpoint outcome measure calculation is required for this study.  
However,  to ensure  statistical  significance,  up to 50 subjects  will be  enrolled.  
 
 
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been  
met, a subject number will be assigned. Subjects will receive a unique identifying number that will be  
composed of a two -digit site number and a three digit subject number in sequence.  This unique  
identifier will be used throughout the entire study and will be entered in the subject's case report form  
(CRF) and for each treatment. Subjects are not randomized; this is an open -label, baseline -controlled,  
evaluator -blind  multi -center study.  
 
 
This is an open -label, baseline -controlled, evaluator -blind multi -center study; only the independent  
reviewers  will be  blinded.  
10.6  MEASURES  TO MINIMIZE  BIAS  
10.6.1  ENROLLMENT/  RANDOMIZATION/  MASKING  PROCEDURES  
10.6.2  EVALUATION  OF SUCCESS  OF BLINDING  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  27 of 32  
  
 
 
Not applicable.  
 
 
Each participating site will maintain appropriate medical and research records for this trial, in  
compliance with ICH E6, ISO 14155:2011, HIPAA and regulatory and institutional requirements for the  
protection of confidentiality of particip ants.  Each site will permit authorized representatives of the  
study sponsor and regulatory agencies to examine (and when permitted by applicable law, to copy)  
clinical records for the purposes of quality assurance reviews, audits, and evaluation of the stu dy safety,  
progress,  and data  validity.  
 
Source data are all information, original records of clinical findings, observations, or other activities in a  
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original  
documents and data records include, but are not limited to, hospital records, clinical and office charts,  
laboratory notes, memoranda, participants' memory aids or evaluation checklists, pharmacy dispensing  
records, recorded audio tapes of counsel ing sessions, recorded data from automated instruments,  
copies or transcriptions certified after verification as being accurate and complete, microfiches,  
photographic negatives, microfilm or magnetic media, x -rays, and participant files and records kept a t 
the pharmacy,  at the laboratories, and  medico -technical  departments  involved in  the clinical  trial.  
 
It is acceptable to use CRFs as source documents. The subject self -reported modified Simple Lifestyle  
Indicator Questionnaire, 5 -point Likert Subject satisfaction Scale, treatment evaluation and visual pain  
scale data for this study will be collected on the CRF.  The immediate response as assessed by the  
principal investigator will be collected on the CRF with the remainder of the data collected from other  
sources.  It is not acceptable for the CRF to be the only record of a subject’s participation in the study.  
This is to ensure that anyone who would access the patient medical record has adequate knowledge  
that the patient  is participating  in a cl inical  trial.  
 
 
Prior to any independent use of the Venus Bliss ™ investigational device, study personnel will receive  
proper training from the sponsor.  Site personnel will be trained on the use of the device prior to study  
initiation at the site.  Additional training requirements will be discussed during study initiation and will  
include site responsibilities, and study documentation.  In addition, the sponsor will provide protocol  
specific training for t he site.  The site will document which individual has been assigned to a specific task  
and will ensure  that appropriate training  has occurred  for that task.  
 
Regular monitoring and an independent audit, if conducted, must be performed according to ICH -GCP 
and ISO 14155:2011.  See also Section  9, Clinical  Monitoring . 
 
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC  
checks that will be run on the database will be generated. Any missing data or data anomalies will be  
communicated  to the site(s) for  clarification/resolution.  
 
Monitors will verify that the clinical trial is conducted and data are generated, documented (recorded),  
and reported  in compliance with  the protocol, GCP,  and the applicable regu latory  requirements.  
10.6.3  BREAKING  THE STUDY  BLIND/PARTICIPANT  CODE  
11 SOURCE  DOCUMENTS  AND  ACCESS  TO SOURCE  DATA/DOCUMENTS  
12 QUALITY  ASSURANCE  AND  QUALITY  CONTROL  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  28 of 32  
  
The investigational site will provide direct access to all trial related sites, source data/documents, and  
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and  
regulatory authori ties.  
 
 
 
The investigator will ensure that this study is conducted in full conformity with Regulations for the  
Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56,  
and/or the ICH E6, the Declaration of Helsinki, Council for International Organizations of Medical Science  
(CIOMS), ISO 14155:2011, International Ethical Guidelines for Biomedical Research Involving Human  
Subjects (2002), or anothe r country’s ethical policy statement, whichever provides the most protection  
to human  subjects.  
 
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be  
submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must  
be obtained before any participant is enrolled.  Any amendment to the protocol will require review and  
approval by the IRB before the changes are implemented to the study.  All changes to the consent form  
will be IRB approved; a determination will be made regarding whether previously consented participants  
need  to be re -consented.  
 
 
 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed  
consent, the investigator should comply with applicable regulatory requirements and should adhere to  
45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, or equivalent local regulatory regulations or guidelines  
and/or ICH GCP.  Prior to the beginning of a trial, the investigator should have the IRB's written approval  
for the protocol and the written informed consent forms(s) and any other written information to be  
provided to the participants.  Consent forms describing in detail the study agent, study procedures, and  
risks are given to the participant and written documentation of informed consent is required prior to  
starting  inter vention/administering  study product.  
 
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the  
study and continues throughout the individual’s study participation.  Extensive discussion of risks and  
possible benefits of participation will be provided to the participants and their families.  Consent forms  
will be IRB -approved and the participant will be asked to read and review the document.  The 
investiga tor will explain the research study to the participant and answer any questions that may arise.  
All participants will receive a verbal explanation in terms suited to their comprehension of the purposes,  
procedures,  and potential  risks  of the study  and of their rights  as research  participants.  Participants  will 
13 ETHICS/PROTECTION  OF HUMAN  SUBJECTS  
13.1  ETHICAL  STANDARD  
13.2  INSTITUTIONAL  REVIEW  BOARD  
13.3  INFORMED  CONSENT  PROCESS  
13.3.1  CONSENT/ASSENT  AND  OTHER  INFORMATIONAL  DOCUMENTS  PROVIDED  TO 
PARTICIPANTS  
13.3.2  CONSENT  PROCEDURES  AND  DOCUMENTATION  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  29 of 32  
  
have the opportunity to carefully review the written consent form and ask questions prior to signing.  
The participants should have the opportunity to discuss the study with their surrogates or think about it  
prior to agreeing to participate.  The participant will sign the informed consent document prior to any  
procedures being done specifically for the study.  The participants may withdraw consent at any time  
throughout the course of  the trial.  A copy of the informed consent document will be given to the  
participants for their records.  The rights and welfare of the participants will be protected by  
emphasizing to them that the quality of their medical care will not be adversely affect ed if they decline  
to participate  in this study.  
 
 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the  
sponsor(s) and their agents.  This confidentiality  is extended to cover testing of biological samples and  
genetic tests in addition to the clinical information relating to participants.  Therefore, the study  
protocol, documentation, data, and all other information generated will be held in strict confidenc e. No 
information concerning the study or the data will be released to any unauthorized third party without  
prior  written approval  of the sponsor.  
 
The study monitor, other authorized representatives of the sponsor, representatives of the IRB or device  
company supplying study product may inspect all documents and records required to be maintained by  
the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy  
records  for the participants  in this  study.  The clinical  study  site will permit access  to such  records.  
 
The study participant’s contact information will be securely stored at each clinical site for internal use  
during the study.  At the end of the study, all records will continue to be kept in a se cure location for as  
long  a period  as dictated by the  sponsor, local IRB and  any other  regulations.  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will  
be transmitted to and stored at the sponsor’s  office.  This will not include the participant’s contact or  
identifying information.  Rather, individual participants and their research data will be identified by a  
unique study identification number.  The study data entry and study management systems used by  
clinical sites and by sponsor’s research staff will be secured and password protected.  At the end of the  
study,  all study databases  will be de-identified  and archived  by the sponsor.  
 
 
The investigator  will store  all data  according  to the  local  regulatory  standards.  
 
 
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site  
PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of  
the data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation  
of data.  Black  ink is  required to ensure  clarity  of reproduced copies.  When  making  changes  or 
13.4  PARTICIPANT  AND  DATA  CONFIDENTIALITY  
13.4.1  RESEARCH  USE  OF STORED  HUMAN  SAMPLES,  SPECIMENS  OR DATA  
14 DATA  HANDLING  AND  RECORD  KEEPING  
14.1  DATA  COLLECTION  AND  MANAGEMENT  RESPONSIBILITIES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  30 of 32  
  
corrections, cross out the original entry with a single line, and initial and date the change. DO NOT  
ERASE,  OVERWRITE,  OR USE CORRECTION  FLUID  OR TAPE ON  THE ORIGINAL.  
 
Copies of the paper CRF will be provided for use as source documents and maintained for recording data  
for each participant enrolled in the study.  Data reported in the CRF derived from source documents  
shou ld be consistent with the source documents or the discrepancies should be explained and captured  
in a progress note and maintained in the participant’s official study record.  Self-reported subject data  
recorded on the non -carbon copy CRF page is permitted.  The original form will be collected by the  
sponsor  and the copy will  remain  at the  site.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical  
laboratory data from paper CRFs will be collected by the stu dy sponsor and will be entered directly onto  
paper  CRFs from  the source  documents.  
 
 
Study documents, including copies of the paper CRFs, signed informed consent forms, photographs,  
laboratory results, medical records, data clarification forms and regulatory documents, should be  
retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and  
until there are no pending or contemplated marketing applications in an ICH regi on or until at least 2  
years have elapsed since the formal discontinuation of clinical development of the investigational  
product.  These documents should be retained for a longer period, however, if required by local  
regulations.  No records will be destroy ed without the written consent of the sponsor, if applicable. It is  
the responsibility of the sponsor to inform the investigator when these documents no longer need to be  
retained.  
 
 
A protocol deviation is any noncompliance with the clinical trial protocol or GCP requirements. The  
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a  
result  of deviations,  corrective  actions  are to be  developed  by the site and implemented promptly.  
These  practices  are consistent  with  ISO 14155:2011  and ICH E6: 
• 4.5 Compliance  with  Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
• 5.1 Quality  Assurance and  Quality Control,  section  5.1.1  
• 5.20  Noncompliance,  sections  5.20.1,  and 5.20.2.  
It is the responsibility of the site to use continuous vigilance to identify and report deviations within 10  
working days of identification of the protocol deviation, or within 10 working days of the scheduled  
protocol -required activity. All deviat ions must be addressed in study source documents. Protocol  
deviations must be sent to the local IRB per their guidelines. The site PI/study staff is responsible for  
knowing  and adhering  to their IRB requirements.  
 
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a  
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any  
research  project  that prospectively  assigns  human  subjects  to intervention  or concurrent comparison  or 
14.2  STUDY  RECORDS  RETENTION  
14.3  PROTOCOL  DEVIATIONS  
14.4  PUBLICATION  AND  DATA  SHARING  POLICY  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  31 of 32  
  
control groups to study the cause -and-effect relationship between a medical intervention and a health  
outcome. Medical interventions include drugs, surgical pro cedures, devices, behavioral treatments,  
process -of-care changes, and the like. Health outcomes include any biomedical or health -related  
measures obtained in patients or participants and adverse events.  The ICMJE policy, and the Section  
801 of the Food and  Drug Administration Amendments Act of 2007, requires that all clinical trials be  
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library  
of Medicine. Other biomedical journals are considering adopting similar policies. The ICMJE does not  
review specific studies to determine whether registration is necessary; instead, the committee  
recommends that researchers who have questions about the need to register err on the side of  
registrati on or consult  the editorial  office  of the  journal in  which  they  wish  to publish.  
 
The sponsor or designated principal investigator will register and report results of certain "applicable  
clinical  trials":  
 
• Trials of Devices: Controlled trials with health o utcomes of a product subject to Health Canada  
or FDA regulation (other than small feasibility studies) and pediatric post market surveillance  
studies.  
 
 
 
The study  will be administered  by the sponsor.  
 
 
The independence of this study from any actual or perceived influence, such as by the device industry, is  
critical.  Therefore, any actual conflict of interest of persons who have a role in the design, conduct,  
analysis, publication, or any aspect of this trial will be disclosed and managed.  Furthermore, persons  
who have a perceived conflict of interest will be required to have such conflicts managed in a way that is  
appropriate to their participation in  the trial.  The sponsor will ensure that all study group members  
disclose all conflicts of interest and will establish a mechanism for the management of all reported  
dualities  of interest.  
 
 
Alizadeh Z, Halabchi F, Mazaheri R, e t al. Review of the Mechanisms and Effects of Noninvasive Body  
Contouring Devices on Cellulite and Subcutaneous Fat.  Int J Endorcrinol Metab. 2016 Oct; 14(4):  
e36727.  
 
Auh SL, Iyengar S, Weil A, Bolotin D et al.  Quantification of Noninvasive Fat Reduction:  A Systematic  
Review.  Laser in  Surg  Med.  2018  50: 96-110.  
 
Bass  LS, Doherty  ST. Safety  and Efficacy  of a noninvasive  1060nm  Diode Laser  for Fat Reduction  of the 
Abdomen.  J Drugs  Dermatol.  2018  17(1):  106-112 
 
Chilukuri S, Mueller G.  “Hands Free” Noninvasive Body contouring Devices:  Review of Effectiveness and  
Patient  Satisfaction.  J Drugs  Dermatol.  2016  15(11):  1402 -1406.  
15 STUDY  ADMINISTRATION  
15.1  STUDY  LEADERSHIP  
16 CONFLICT  OF INTEREST  POLICY  
17 LITERATURE  REFERENCES  
Diode  Laser  for Non-invasive  Fat Reduction  of the Abdomen  
Protocol  #CS1317  Version  1.0 
19 September  2018  
Page  32 of 32  
  
Decorato JW, Chen B, Sierra R.  Subcutaneous Adipose Tissue Response to a Non -Invasive Hyperthermic  
Treatment  using  a 1060nm  Laser.  Lasers in  Surg  Med.  2017  49(5):  480-489.  
 
Godwin M, Pike A, Bethune C et al. Concurrent and Convergent Validity of the Simple Lifestyle Indicator  
Questionnaire.  ISRN  Family Medicine  Volume  2013,  Article ID 529645,  6 pages.  
 
Katz B, Doherty S.  Safety and Efficacy of a Noninvasive 1060nm Diode Laser for Fat Reduction of the  
Flanks.  Dermatol  Surg.  2018 44(3):  388-396.  
 
McBean  JC, Katz  BE. Laser  Lipolysis:  An Update.  J Clin  Aesthetic Derm.  2011  4(7):  25-34. 
 
Schilling L, Saedi N, Weiss R. 1060 nm Diode Hyperthermic Laser Lipolysis: The Latest in Non -Invasive  
Body  Contouring. J  Drugs  Dermatol.  2017  Jan 1;16(1):48 -52. 
 
 
Version  Date  Significant  Revisions  
   
   
 
APPENDIX  